CDMO News and Research

RSS

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

In this interview, Niall Dinwoodie, Executive Director for Gene Therapy for Charles River in Europe discusses the opening of their new HQ Plasmid Center of Excellence at Alderley Park.

From Charles Rivers Laboratories Cell and Gene Therapy 4 Nov 2022

Celebrating the Alderley Park Grand Opening

HQ Plasmid Center of Excellence based at UK life science hotspot now open for business.

From Charles Rivers Laboratories Cell and Gene Therapy 24 Oct 2022

Monon Bioventures receives SBIR grant to develop glioblastoma therapeutic created at Purdue

Monon Bioventures LLC has received a one-year, $398,314 Phase I Small Business Innovation Research, or SBIR grant from the National Cancer Institute to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy.

22 Sep 2022

Evonik now offers enteric protected ready to fill capsules EUDRACAP® in IPEC-GMP quality

Evonik’s EUDRACAP® enteric easy-to-handle capsules are now globally available produced under IPEC-GMP. Launched last year, EUDRACAP® enteric are functional, ready-to-fill capsules that help pharmaceutical companies bring complex oral drug products to market faster.

From Evonik Health Care 14 Jul 2022

DZNE and Intravacc receive € 2.5 million EU funding to develop a prototype ALS vaccine

DZNE and Intravacc B.V., a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines, have been awarded a funding of € 2.5 million from the European Union (EIC Transition Grant) to further develop a prototype ALS vaccine, including process development, scale-up, and toxicology study.

6 Jul 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From Bruker Cellular Analysis 6 Jun 2022

VectorBuilder to expand with $500 million ‘Gene Delivery Research and Manufacturing Campus

VectorBuilder Inc. has announced the construction of a new R&D and manufacturing center in Guangzhou, China.

From VectorBuilder 12 Apr 2022

Understanding and overcoming the challenges of chemical synthesis at a global Contract Research Organisation

In this interview, News-Medical talks to Andrew Kennedy and Jono West from Sai Life Sciences, about the work they do and how they utilise Radleys equipment in order to understand and overcome chemical synthesis challenges.

From Radleys 5 Jan 2022

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

Leading Producer of Controlled Substance APIs Now Supplying Lisdex API to Generic Drug Manufacturers Preparing for the 2023 Patent Expiry of Top-Selling Branded ADHD Therapy.

3 Dec 2021

Purisys Adds ISO Certifications Confirming Its Commitment to Quality and Excellence

Purisys LLC, a leading supplier of active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) services, and pharmaceutical reference materials, today announced that it has obtained two additional global ISO certifications: ISO 17025 (Testing and Calibration Laboratories) and ISO 17034 (Reference Materials Producers).

From Purisys 9 Jul 2021

LGM Pharma launches standalone analytical services for drug developers and manufacturers

LGM Pharma today announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies.

From LGM Pharma 8 Jul 2021

SwiftScale Biologics: Cell-Free Synthesis of Biologics

In this interview, News-Medical talks to David Mace, CEO at SwiftScale Biologics, about the work they do in cell-free synthesis, their partnership with Sartorius and the biologics field as a whole.

From Sartorius 30 Mar 2021

Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccine

Caused by SARS-CoV-2, the coronavirus disease 2019 (COVID-19) pandemic continues to spread across the globe.

From Evonik 2 Mar 2021

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent and Delphi Genetics today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

26 Feb 2021

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent and Delphi Genetics today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

26 Feb 2021

Cobra Biologics successfully produced master cell banks for CombiGene’s gene therapy

Cobra Biologics, part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and CombiGene AB, the leading gene therapy company in the Nordic region, today announced that Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.

21 Aug 2020

Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate

Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.

From AstraZeneca 17 Jun 2020

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19.

21 May 2020

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

Rentschler Biopharma SE, and Horizon Discovery, a leader in the application of gene editing, today announced the signing of a commercial license agreement.

From Revvity 19 May 2020

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

FDB announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies.

From OXGENE 23 Apr 2020

CDMO News and Research

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

Celebrating the Alderley Park Grand Opening

Monon Bioventures receives SBIR grant to develop glioblastoma therapeutic created at Purdue

Evonik now offers enteric protected ready to fill capsules EUDRACAP® in IPEC-GMP quality

DZNE and Intravacc receive € 2.5 million EU funding to develop a prototype ALS vaccine

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

VectorBuilder to expand with $500 million ‘Gene Delivery Research and Manufacturing Campus

Understanding and overcoming the challenges of chemical synthesis at a global Contract Research Organisation

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

Purisys Adds ISO Certifications Confirming Its Commitment to Quality and Excellence

LGM Pharma launches standalone analytical services for drug developers and manufacturers

SwiftScale Biologics: Cell-Free Synthesis of Biologics

Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccine

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Cobra Biologics successfully produced master cell banks for CombiGene’s gene therapy

Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News